Hansoh Pharmaceutical Group Company Limited
3692
Classificação em ações
#903
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Preço da ação
$4.38
Valor de mercado
$26.56B
Variação (1 dia)
-0.38%
Variação (1 ano)
-5.15%
País
CN
Negociar Hansoh Pharmaceutical Group Company Limited (3692)
Categoria
Healthcare
Receita da Hansoh Pharmaceutical Group Company Limited (3692)
Receita em Jun 2026 TTM: $2.30B
De acordo com os últimos relatórios financeiros da Hansoh Pharmaceutical Group Company Limited, a receita atual da empresa (TTM) é $2.30B. Em 2023, a empresa obteve uma receita de $1.43B um aumento em relação a a receita do ano 2022, que foi de $1.36B. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Hansoh Pharmaceutical Group Company Limited de 2016 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $2.30B | 37.16% |
| 2024 | $1.68B | 17.68% |
| 2023 | $1.43B | 4.94% |
| 2022 | $1.36B | -12.98% |
| 2021 | $1.56B | 17.51% |
| 2020 | $1.33B | 6.68% |
| 2019 | $1.25B | 11.07% |
| 2018 | $1.12B | 18.09% |
| 2017 | $950.71M | 21.49% |
| 2016 | $782.52M | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 186.97% |
IN
|
